Prostate 2 Flashcards

1
Q

What are four very high risk features of prsotate cancer?

A

cT3b-T4
Primary Gleason 5
2 or 3 high risk features
>4 cores with GG4 or 5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are three high risk features in prostate? How many do you need to qualify as high risk?

A

Exactly one of:
cT3
GG4 or GG5
PSA >20

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How to differentiate unfavorable intermediate vs favorable?

A

Unfavorable has GG3 or >50% biopsy cores positive
Favorable has GG 1-2 or <50% cores positive
Unfavorable also has 2 or 3 intermediate risk factors vs 1 (T2b=T2c, GG 2 or 3, PSA 10-20)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When to order bone scan or soft tissue imaging in newly diagnosed prostate cancer?

A

Unfavorable intermediate risk or higher

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

who is appropriate for active surveillance?

A

Very low risk with 10-20 year survival
low risk with at least 10 year survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Definition of PSA recurrence after surgery?

A

PSA >0.1 or 2 or more increases
PSA persistence is never becoming undetectable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Definition of PSA recurrence after RT?

A

Increase by 2ng/mL above nadir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Preferred treatment strategy for de novo metastatic HSPC with high volume disease?

A

ADT + Docetaxel + Abiraterone/Darolutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment options for de novo metastatic HSPC without high volume disease? (3)

A

ADT+ Abi, apa, enza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the effect on survival for radiation to oligometastatic disease?

A

Improves PFS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment options for M0 CRPC (3)

A

ADT +
Apa
Enza
Daro

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which is more common in prostate cancer, BRCA2 or BRCA1?

A

BRCA2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

4 PARPi that are approved for mCRPC

A

Olaparib
Rucaparib
Talazoparib +/- Enzalutamide
Niraparib + Abiraterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Definition of high volume metastatic disesase

A

Visceral mets or
4 or more bone mets (at least one met beyond pelvis-vertebrae)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

4 adverse findings to be seen on a prostatectomy specimen

A

POstiive margin
seminal vesicle involvement
extracapsular extension (pT3a)
Detectable PSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the difference between adjuvant RT and observation then salvage RT in patients with adverse findings after prostatectomy?

A

More toxicity in adjuvant RT, no benefit in survival compared to salvage RT

17
Q

What types of patients with mCRPC are candidates for Sipuleucel-T?

A

Asymptomatic or minimally symptomatic
No liver mets
ECOG 0-1

18
Q

Treatment options (2) for unfavorable intermediate risk disease?

A

RP + PLND or
EBRT + ADT 4-6 months

19
Q

Treatment for favorable intermediate disease with life expectancy >10 years (3)

A

Surveillance
EBRT
Prostatectomy +/- PLND

20
Q

Treatment for high-risk prostate cancer?

A

EBRT + ADT (long term)
EBRT + ADT + Abi (if PSA >40)
RP + PLND

21
Q

Patient with unfav intermed disease goes for upfront RP and PLND. Has extracapsular extension, positive margins, and 1 LN was positive. Treatment?

A

Adjuvant ADT + EBRT
Technically could observe but nobody does

22
Q

Preferred treatment for mCRPC that has progressed on docetaxel and abi (or enza)?

A

Cabazitaxel

23
Q

Indication for niraparib + abi?

A

mCRPC with BRCA mutation

24
Q

Indication for olaparib+Abi

A

mCRPC with BRCA mutation

25
Q

Indication for Talazoparib + Enza

A

mCRPC with HRR mutation (BRCA 1/2, ATM, CDK12, CHEK2, MLH1, PALB2, RAD51C)

26
Q

Indications for enzalutamide + ADT in the biochemical recurrent setting

A

High risk:
PSADT <9 mon
PSA >2 above RT nadir or >1 after RP +/- postop RT